UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 4,700 shares, an increase of 2,250.0% from the December 31st total of 200 shares. Based on an average daily volume of 13,700 shares, the days-to-cover ratio is presently 0.3 days.

UCB Price Performance

UCBJY traded down $0.48 on Tuesday, hitting $98.22. 45,810 shares of the stock were exchanged, compared to its average volume of 7,263. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 12 month low of $46.00 and a 12 month high of $100.66. The business has a 50-day moving average of $96.95 and a two-hundred day moving average of $91.99.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.